Treasury and IRS Signal 280E Relief Is Coming for Medical Cannabis Operators

For cannabis operators who have spent years absorbing some of the most punishing effective tax rates in American business, a joint statement from the Treasury Department and the Internal Revenue Service may be the most consequential paragraph they read this year.

In a press release issued April 30, the two federal agencies said they “expect DOJ’s action to have significant positive tax consequences for businesses in the medical marijuana industry” — and promised that formal tax guidance is forthcoming. The statement is the clearest indication yet that the Trump administration’s partial cannabis rescheduling move, confusing as its legal mechanics have been, is about to translate into material financial relief for state-licensed medical cannabis businesses.

The 280E Problem, in Plain Numbers

To understand why this matters, start with the Internal Revenue Code Section 280E — the provision that has functioned as a de facto federal penalty on the cannabis industry since the 1980s. Under 280E, businesses trafficking in Schedule I or Schedule II controlled substances are barred from deducting ordinary and necessary business expenses. Payroll, rent, marketing, administrative overhead: none of it counts when calculating federal taxable income.

The result has been effective federal tax rates that routinely run between 50 and 80 percent for multistate operators and single-state dispensaries alike — far above what any comparably sized business in any other industry faces. Some publicly traded cannabis companies have reported paying more in federal taxes than they earned in net income in a given year. For smaller operators already operating on thin margins in competitive state markets, 280E hasn’t just squeezed profits — it has forced layoffs, accelerated store closures, and contributed to the wave of cannabis company bankruptcies and restructurings that has defined the past two years.

The industry has waited on rescheduling partly for symbolic reasons, but mostly for this: the possibility that a Schedule III classification would pull cannabis out of 280E’s reach entirely.

What the Treasury Statement Actually Says

The joint Treasury-IRS release frames its expectation around the DOJ’s rescheduling action — the same executive move that The Guardian and other outlets described as “partial” and potentially legally confusing in its scope. Experts cited in reporting from late April noted that the administration’s reclassification order was limited to medical marijuana and stopped short of the full Schedule III shift that DEA rulemaking would require. Whether that distinction survives legal challenge remains an open question.

What is notable is that Treasury and the IRS are treating the DOJ action as sufficient to trigger at least some tax relief for state-licensed medical marijuana businesses. That’s a meaningful signal. Federal agencies don’t typically preview guidance they aren’t prepared to deliver.

The agencies did not provide a timeline for when formal guidance will be published, and they did not specify how relief would be structured — whether operators could immediately begin treating cannabis as exempt from 280E, whether they would need to wait for a final IRS ruling, or whether guidance would apply retroactively to prior tax years. Those details matter enormously to CFOs and tax counsel across the industry.

Operator Impact: Who Stands to Gain Most

The operators with the most to gain from 280E relief are the mid-size and large vertically integrated companies that carry the highest absolute tax burdens. Multistate operators with significant cultivation and processing operations — the backbone of the regulated market in states like Illinois, Pennsylvania, Ohio, and Massachusetts — have been particularly exposed because they carry large payrolls and overhead structures that they cannot currently deduct.

If 280E no longer applies to medical cannabis businesses, those companies could see their effective federal tax rates drop toward something closer to the 21 percent statutory corporate rate — or lower, once standard deductions are factored in. The cash flow implications are significant. For a company paying $20 million in annual federal taxes on $30 million in gross revenue, a shift to standard corporate taxation could mean the difference between burning cash and generating it.

The picture is more complicated for operators with mixed medical and adult-use portfolios. If DOJ’s action only covers medical marijuana, companies with adult-use retail and cultivation operations may face a bifurcated tax situation — a compliance nightmare that tax attorneys are already beginning to model out. Treasury’s forthcoming guidance will need to address that boundary clearly.

Market and Investment Implications

For investors watching cannabis equities — a space that has shed enormous market capitalization since peak valuations in 2021 — the Treasury-IRS statement is meaningful even in the absence of specifics. It represents the first credible federal signal that 280E relief for at least some cannabis businesses is a near-term reality rather than a perpetually deferred possibility.

Cannabis stocks have historically traded on regulatory narrative as much as on fundamentals. The combination of the DOJ rescheduling action and now an explicit Treasury endorsement of its tax consequences gives operators and their investors something they have not had before: a government agency telling them, on record, that the financial math is about to change.

The caveat is the same caveat that has applied to every cannabis federal reform development since 2018: litigation risk. Advocacy groups, competing industry factions, and potentially state-level actors could challenge the DOJ action’s legal basis, and any challenge that succeeds would put Treasury guidance in an awkward position. The administration has shown a willingness to move quickly on cannabis policy, but speed doesn’t insulate executive action from court challenge.

What Operators Should Do Now

Industry attorneys and accountants are already advising clients not to change their tax filing posture until formal IRS guidance is published. The Treasury statement signals intent, not permission. Filing amended returns or restructuring expense accounting before the IRS issues a formal ruling could expose operators to penalties if the guidance ends up narrower than the announcement suggests.

That said, operators should be using this window to model scenarios aggressively. What does cash flow look like if 280E relief applies to 100 percent of operations? To medical only? What is the timeline for when changes could take effect? Companies that have done that modeling will be positioned to move quickly when guidance drops; companies that haven’t will be scrambling.

The gap between a Treasury press release and IRS guidance has historically been measured in months. Given the administration’s stated interest in demonstrating tangible cannabis reform wins, there is reason to expect guidance on the faster end of that range. The industry has been waiting a long time for this particular door to open. It’s not fully open yet — but the lock is turning.

Caleb Quinn covers cannabis business, investment, and policy for CannabisInquirer.com.